Previous 10 | Next 10 |
Can These Penny Stocks Keep Heading Higher? Unless you’ve lived under a rock for the last few months, coronavirus is one of the top headline topics of the year. In fact, some of the highest traffic we’ve seen has come over the last month with a major focus on coronavirus penny s...
BOSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the Barclays Global Healthcare Conference in Miami on Wednesday, March ...
BOSTON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, March 2, at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and year ended D...
Ziopharm Oncology ( ZIOP ) announced its plan to issue equity shares. The company reported that it plans to issue nearly 27.8 million shares, not including underwriters’ overallotment which will likely result in the issue of additional 4.2 million shares. The issue will be priced at $...
Gainers: Myomo (NYSEMKT: MYO ) +98% . More news on: Myomo, Inc., VIVUS, Inc., Predictive Oncology Inc., Stocks on the move, , Read more ...
Shares of Ziopharm Oncology (NASDAQ: ZIOP) fell 14% today after the company announced and priced a public stock offering. The business will sell up to 32 million shares of common stock at $3.25 apiece, which could generate gross proceeds of up to $104 million. The fundraising efforts ...
Ziopharm Oncology (NASDAQ: ZIOP ) slips 6% premarket on modestly higher volume in reaction to its public offering of ~27.8M common shares at $3.25 per share. More news on: ZIOPHARM Oncology, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
BOSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of $3.25 per share. Ziopharm has granted the underwriters a 30-day option to pur...
Gainers: MYO +38.6% . USNA +22.4% . BBAR +4.9% . AOSL +3.5% . YRCW +1.9% . More news on: Myomo, Inc., USANA Health Sciences, Inc., Banco BBVA Argentina S.A., Stocks on the move, , , News on ETFs Read more ...
BOSTON, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Ziopharm. Ziopharm also intends to ...
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...